Research programme: skin disorder therapeutics - Sirona Biochem

Drug Profile

Research programme: skin disorder therapeutics - Sirona Biochem

Latest Information Update: 16 May 2016

Price : $50

At a glance

  • Originator Sirona Biochem
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acne vulgaris; Keloids

Highest Development Phases

  • Preclinical Keloids
  • Research Acne vulgaris

Most Recent Events

  • 16 May 2016 Preclinical trials in Keloids in Canada (unspecified route)
  • 16 May 2016 Early research in Acne vulgaris in Canada (unspecified route)
  • 18 Apr 2016 Research programme: skin care therapeutics - Sirona Biochem is available for licensing after the completion of in-vitro studies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top